
Anixa Biosciences (ANIX) announced that it will work with Curia to provide formulation development services for Anixa’s investigational breast cancer vaccine in preparation for its upcoming Phase 2 clinical trial.
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ANIX | Anixa Biosciences | 2.67 | -1.43 | -34.88% |
| Name | Price | % Change | |
|---|---|---|---|
| $2.67 | -34.88% |

Anixa Biosciences (ANIX) announced that it will work with Curia to provide formulation development services for Anixa’s investigational breast cancer vaccine in preparation for its upcoming Phase 2 clinical trial.

Anixa Biosciences (ANIX) has completed dosing of the fifth cohort in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The sixth

Anixa Biosciences (ANIX) announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stable disease 90 days

Insiders have been trading these 5 stocks: (($APT)), (($XENE)), (($ANIX)), (($VNO)) and (($HDSN)). Here is a breakdown of their recent trades and their value. Director Charles Montgomery’s sale of 35,000

Anixa Biosciences (ANIX) announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Anixa Biosciences (ANIX) to $6 from $7 and keeps a Buy rating on the shares after the company announced

Anixa Biosciences (ANIX) announced that IP Australia has issued Patent Number 2020221280 related to Anixa’s breast cancer vaccine technology, exclusively licensed from Cleveland Clinic. This composition-of-matter patent protects the company’s

Anixa Biosciences (ANIX) announced that IP Australia has issued a Notice of Acceptance for a new patent related to Anixa’s breast cancer vaccine technology. This patent, exclusively licensed from Cleveland

Anixa Biosciences (ANIX) announced that the first patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T/CER-T therapy for

D. Boral Capital analyst Patrick McCann assumed coverage of Anixa Biosciences (ANIX) with a Buy rating and $10 price target The firm says recent presentations highlighted final Phase 1 results
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.